

**Program: Best of ASCO Bangkok 2018 (Day 2: 4 August 2018)**

<b>Time</b>	<b>Abstract ID</b>	<b>Title</b>	<b>Presenter</b>	<b>Moderator</b>
8:00-8:45		<b>Symposium BMS: The Evolving Immuno-Oncology Treatment Landscape in NSCLC and Head and Neck Cancers</b>	<i>Assist.Prof.THORSTEN FUREDER</i> <i>University of Vienna, Austria</i>	<i>Assoc. Prof.VICHIEEN SRIMUNINNIMIT</i>
		<b>Head and neck cancer session</b>		
8:45-8:55	6000	Results of a randomized phase III study of Nimotuzumab in combination with concurrent radiotherapy and Cisplatin versus radiotherapy and Cisplatin alone, in locally advanced squamous cell carcinoma of the head and neck.	<i>CHANIDA VINAYANUWATTIKUN, M.D.</i>	<i>Assist.Prof.CHARUWAN AKEWANLOP</i>
8:55-9:05	6006	Results of a randomized, placebo (PBO) controlled, double-blind P2b trial of GC4419 (avisopasem manganese) to reduce duration, incidence and severity and delay onset of severe radiation-related oral mucositis (SOM) in patients (pts) with locally advanced squamous cell cancer of the oral cavity (OC) or oropharynx (OP).	<i>DANITA KANNARUNIMIT, M.D.</i>	
9:05-9:15	6008	Multicenter Phase II Trial of Palbociclib, a Selective Cyclin Dependent Kinase (CDK) 4/6 Inhibitor, and Cetuximab in Platinum-Resistant HPV Unrelated (-) Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (RM HNSCC).	<i>Assist.Prof.NUTTAPONG NGAMPHAIBOON</i>	
9:15-9:35		Discussion/ Q&A	<i>Discussant: Assist.Prof.THORSTEN FUREDER, Q&amp;A: panelists</i>	
<b>9.40-10.25</b>		<b>Symposium Eisai: HCC management: Current and beyond</b>	<i>Prof.CHIUN HSU</i> <i>Institute of Oncology, College of Medicine,</i> <i>National Taiwan University, Taiwan</i>	<i>Assist.Prof.EKAPHOP SIRACHAINAN</i>
<b>10.25-10.45</b>		<b>Exhibition</b>		
		<b>Non-colorectal gastrointestinal cancer session</b>		
10:45-10:55	LBA4001	Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized controlled phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas.	<i>Assist.Prof. SUEBPONG TANASANVIMON</i>	<i>Assist.Prof.EKAPHOP SIRACHAINAN</i>
10:55-11:05	4007	A randomized phase III study comparing S-1 plus docetaxel with S-1 alone as a postoperative adjuvant chemotherapy for curatively resected stage III gastric cancer (JACCRO GC-07 trial).	<i>Assist.Prof.NUTTAPONG NGAMPHAIBOON</i>	
11:05-11:15	4003	REACH-2: A randomized, double-blind, placebo-controlled phase 3 study of ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP) following first-line sorafenib.	<i>NAIYARAT PRASONGSOOK, M.D.</i>	
11:15-11:35		Discussion/ Q&A	<i>Discussant: Prof.CHIUN HSU, Q&amp;A: panelists</i>	

**Program: Best of ASCO Bangkok 2018 (Day 2: 4 August 2018)**

<b>Time</b>	<b>Abstract ID</b>	<b>Title</b>	<b>Presenter</b>	<b>Moderator</b>
<b>Genitourinary cancer session</b>				
11:35-11:47	LBA3	CARMENA: Cytoreductive nephrectomy followed by sunitinib versus sunitinib alone in metastatic renal cell carcinoma—Results of a phase III noninferiority trial.	Assist.Prof.THITIYA DEJTHEVAPORN	KASAN SEETALAROM, M.D.
11:47-11:59	4500	Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): results from cohort A of KEYNOTE-427.	PONGWUT DANCHIVIJITR, M.D.	
11:59-12:11	5000	A randomized phase III trial between adjuvant docetaxel and surveillance after radical radiotherapy for intermediate and high risk prostate cancer: Results of SPCG-13 trial.	Assoc.Prof.CHAIYUT CHAROENTUM	
12:11-12:25		Q&A		
<b>12:30-13:15</b>	<b>Lunch symposium MSD: A Renaissance of Checkpoint Immunotherapy in Advanced NSCLC treatment</b>		<b>Clinical Assoc.Prof. JAMES HO</b> Department of Medicine, The University of Hong Kong, Hong Kong	<b>Assoc.Prof.VIOTE SRIURANPONG</b>
13:15-13:30	Exhibition			
<b>Lung cancer session</b>				
13:30-13:40	LBA9000	IMpower131: Primary PFS and Safety Analysis of a Randomized Phase III Study of Atezolizumab + Carboplatin + Paclitaxel or Nab-Paclitaxel vs Carboplatin + nab-Paclitaxel as 1L Therapy in Advanced Squamous NSCLC.	NAIYARAT PRASONGSOOK, M.D.	Assoc.Prof.VIOTE SRIURANPONG
13:40-13:50	LBA4	Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study.	Assist.Prof.THANYANAN REUNGWETWATTANA	
13:50-14:00	9001	Nivolumab+ platinum-doublet chemotherapy vs chemotherapy as first line treatment for advanced NSCLC with <1% tumor PDL-1 expression: Results from Checkmate 227	CHANIDA VINAYANUWATTIKUN, M.D.	
14:00-14:20		Discussion/ Q&A	<b>Discussant:</b> <b>Assist. Prof.CHARUWAN AKEWANLOP, Q&amp;A:</b> <b>panelists</b>	
14:20-14:30	9006	Phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations. NEJ026.	PIYADA SITTHIDEATPHAIBOON, M.D.	
14:30-14:40	9003	Deleterious effect of baseline steroids on efficacy of PD-(L)1 blockade in patients with NSCLC.	SIRIWIMON SAICHAMCHAN, M.D.	
14:40-14:55		Discussion/ Q&A	<b>Discussant: Clinical Assoc.Prof. JAMES HO ,</b> <b>Q&amp;A: panelists</b>	

**Program: Best of ASCO Bangkok 2018 (Day 2: 4 August 2018)**

<b>Time</b>	<b>Abstract ID</b>	<b>Title</b>	<b>Presenter</b>	<b>Moderator</b>
15:00-15:45		<b>Symposium AstraZeneca: Current and future treatment in HR+ advance breast cancer</b>	<i>Dr. NAN SOON WONG</i> National Cancer Center Singapore, Singapore	<i>Assist.Prof.THITIYA DEJTHEVAPORN</i>
15:45-16:00		<b>Exhibition</b>		
		<b><i>Melanoma and sarcoma session</i></b>		
16:00-16:12	9502	Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: Updated results from a phase III trial (CheckMate 238).	<i>Assoc.Prof.PATRAPIM SUNPAWERAVONG</i>	<i>Clin.Prof. SUDSAWAT LAOHAVINIJ</i>
16:12-16:24	11500	Phase III, randomized, double blind, placebo-controlled trial of sorafenib in desmoid tumors (Alliance A091105).	<i>Assist Prof. CHANYOOT BANDIDWATTANAWONG</i>	
16:24-16:36	11503	Anlotinib for metastasis soft tissue sarcoma: A randomized, double-blind, placebo-controlled and multi-centered clinical trial.	<i>TOUCH ATIVITAVAS, M.D.</i>	
16:36-16:50		Q&A		
16:50		<b>Closing Remark</b>		<i>Assoc.Prof.VIROTE SRIURANPONG</i>